BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Huang LC, Wong JR, Alonso-Llamazares J, Nousari CH, Perez VL, Amescua G, Karp CL, Galor A. Pseudopemphigoid as caused by topical drugs and pemphigus disease. World J Ophthalmol 2015; 5(1): 1-15 [DOI: 10.5318/wjo.v5.i1.1]
URL: https://www.wjgnet.com/2218-6239/full/v5/i1/1.htm
Number Citing Articles
1
E Montolío-Marzo, CD Méndez-Hernandez, D Díaz-Valle, A Ruiz-Guijosa, C Heredia-Pastor, A Milans-del-Bosch. Pseudopemphigoid after long-term medical glaucoma treatmentJournal Français d'Ophtalmologie 2022; 45(8): e374 doi: 10.1016/j.jfo.2021.12.025
2
Sowmya Andole, Sirisha Senthil. Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management GuidelinesSeminars in Ophthalmology 2023; 38(2): 158 doi: 10.1080/08820538.2022.2094714
3
Facundo Urbinati, Davide Borroni, Marina Rodríguez-Calvo-de-Mora, José-María Sánchez-González, María García-Lorente, Francisco Zamorano-Martín, Rahul Rachwani-Anil, Santiago Ortiz-Pérez, Vito Romano, Carlos Rocha-de-Lossada. Pseudopterygium: An Algorithm Approach Based on the Current EvidenceDiagnostics 2022; 12(8): 1843 doi: 10.3390/diagnostics12081843
4
Sravanthi Vegunta, Alison V. Crum. Smith and Nesi’s Ophthalmic Plastic and Reconstructive Surgery2021; : 231 doi: 10.1007/978-3-030-41720-8_12
5
Patrick Michael Jedlowski, Mahdieh Fazel Jedlowski. Topical ophthalmic beta‐blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting systemAustralasian Journal of Dermatology 2022; 63(2): 222 doi: 10.1111/ajd.13828
6
Olivia Chukwuma, Sami K. Saikaly, Marjorie Montanez-Wiscovich, Caroline Winslow, Kiran Motaparthi. Ocular pseudopemphigoid with concomitant eyelid dermatitis secondary to rosaceaJAAD Case Reports 2021; 7: 62 doi: 10.1016/j.jdcr.2020.11.007